3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
2
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
56
Squamous Cell Carcinoma of Head and Neck
31
Lung Neoplasms
17
Head and Neck Neoplasms
17
Urinary Bladder Neoplasms
16
Oropharyngeal Neoplasms
14
Nasopharyngeal Carcinoma
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Carcinoma
10
Small Cell Lung Carcinoma
9
Carcinoma, Squamous Cell
9
Uterine Cervical Neoplasms
8
Pancreatic Neoplasms
8
Ovarian Neoplasms
8
Carcinoma, Transitional Cell
8
Neoplasm Metastasis
7
Mouth Neoplasms
7
Breast Neoplasms
7
Triple Negative Breast Neoplasms
6
Recurrence
6
Neoplasms
6
Melanoma
6
Gallbladder Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Esophageal Neoplasms
6
Colorectal Neoplasms
6
Biliary Tract Neoplasms
6
Mesothelioma, Malignant
5
Medulloblastoma
5
Laryngeal Neoplasms
5
Interventions
Paclitaxel
6
Cyclophosphamide
5
pembrolizumab
3
Taxes
3
Specimen Handling
3
Doxorubicin
3
Carboplatin
3
eribulin
2
Trastuzumab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
sargramostim
1
ruxolitinib
1
pertuzumab
1
onvansertib
1
olaparib
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Therapeutics
1
Radiotherapy
1
Radiation
1
Panitumumab
1
Palliative Care
1
Methods
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Gonadotropin-Releasing Hormone
1
Exercise Test
1
Epirubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Inflammatory Breast Neoplasms
×
Cisplatin
×
Clear all
NCT02221999
2023-08-29
SHPD002
RenJi Hospital
Phase 2/3
Active not recruiting
250 enrolled